Delivery Order SPE2DR25D6038-SPE2DR26F95JK
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,073.56 to AmerisourceBergen Drug Corp for VIMPAT 150 mg tablets (60 unit dose tablets) on October 21, 2025, with a completion date of October 22, 2025. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for VIMPAT 200 mg tablets (60-count) on October 27, 2025, with a ceiling value of $2,117.02. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 28, 2025. The award represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,689.20 to AmerisourceBergen Drug Corp for VIMPAT 200 mg tablets (60-count supply). This competitive, non-set-aside contract was awarded on September 25, 2025, with an ultimate completion date of September 26, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, under firm fixed-price terms. This delivery order is a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of VIMPAT 200 mg/20 ml vials valued at $1,365.00. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for the supply of VIMPAT 150 mg tablets (60 count) valued at $1,013.36. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of September 5, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a single transaction under...
- AmerisourceBergen Drug Corp was awarded a delivery order on October 14, 2025, by the Defense Logistics Agency for VIMPAT 200 mg tablets (60-count units) with a ceiling value of $1,180.74. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 15, 2025. The award represents a continuation of pharmaceutical supply services to support federal medical procurement needs, with performance taking place at the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $3,707.00 to AmerisourceBergen Drug Corp for the supply of VIMPAT 100 mg tablets (60-count units). This contract, issued on September 22, 2025, with an ultimate completion date of September 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of VIMPAT 100 mg at a ceiling value of $1,089.84 under a firm fixed price contract type. This award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of VIMPAT 100 mg tablets (60-count units) valued at $2,048.51. This firm fixed-price delivery order, which is expected to be completed by August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of VIMPAT 10 mg/mL solution in 200 mL quantities, valued at $1,959.86. This competitively awarded, firm fixed-price delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The contract carries no set-aside designation and will...
- SPE2DR25D6038Indefinite Delivery Contract
- SPE2DR25D6038-SPE2DR26F95JKDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order by the Defense Logistics Agency (DLA) on October 28, 2025, for the supply of VIMPAT 150 mg tablets (60 tablets) valued at $1,255.40. This award is a firm fixed-price delivery order with an ultimate completion date of October 29, 2025, and carries no set-aside designation. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at approximately $1 billion through December 2026. VIMPAT (lacosamide) is an antiepileptic medication used in the treatment of partial-onset seizures, reflecting AmerisourceBergen's broad portfolio of specialized pharmaceutical products serving the Defense Health Agency and related federal healthcare programs. The contract demonstrates the company's continued capability to fulfill federal procurement requirements for essential medications across multiple therapeutic domains on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 10/28/25 |